Victory Capital Management Inc. Purchases 21,135 Shares of Moderna, Inc. (NASDAQ:MRNA)

Victory Capital Management Inc. increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 7.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 303,132 shares of the company's stock after purchasing an additional 21,135 shares during the period. Victory Capital Management Inc. owned approximately 0.08% of Moderna worth $30,146,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Arlington Trust Co LLC increased its position in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock valued at $29,000 after purchasing an additional 290 shares during the period. Archer Investment Corp lifted its holdings in shares of Moderna by 71.2% during the 3rd quarter. Archer Investment Corp now owns 534 shares of the company's stock worth $55,000 after acquiring an additional 222 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Moderna by 44.9% during the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company's stock valued at $58,000 after acquiring an additional 175 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in Moderna by 408.3% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 610 shares of the company's stock valued at $63,000 after acquiring an additional 490 shares during the period. Finally, Hexagon Capital Partners LLC raised its position in Moderna by 182.4% in the fourth quarter. Hexagon Capital Partners LLC now owns 610 shares of the company's stock worth $61,000 after purchasing an additional 394 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Trading Up 0.7 %

NASDAQ:MRNA traded up $0.82 on Wednesday, hitting $121.89. 2,505,444 shares of the stock were exchanged, compared to its average volume of 4,110,163. The stock has a market capitalization of $46.71 billion, a price-to-earnings ratio of -7.78 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $142.79. The company's 50-day moving average price is $106.59 and its 200 day moving average price is $95.24.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analysts' expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business's revenue for the quarter was down 91.0% on a year-over-year basis. During the same period last year, the firm earned $0.19 earnings per share. On average, equities research analysts forecast that Moderna, Inc. will post -7.47 earnings per share for the current year.

Insider Activity at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the business's stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the completion of the transaction, the director now directly owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Moderna news, CFO James M. Mock sold 705 shares of the business's stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the transaction, the chief financial officer now directly owns 5,048 shares of the company's stock, valued at $514,542.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00. Following the transaction, the director now owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The disclosure for this sale can be found here. Over the last quarter, insiders sold 139,954 shares of company stock worth $14,822,576. 15.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on MRNA shares. UBS Group upped their price objective on Moderna from $143.00 to $151.00 and gave the company a "buy" rating in a research note on Tuesday. Canaccord Genuity Group lifted their price objective on Moderna from $91.00 to $106.00 and gave the company a "hold" rating in a report on Friday, May 3rd. Royal Bank of Canada increased their target price on shares of Moderna from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Needham & Company LLC restated a "hold" rating on shares of Moderna in a research report on Thursday, May 2nd. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $126.89.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.